Defunct Company
Total Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
221
NCT01439971
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2011
Completion: Oct 31, 2015
NCT03186677
Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
Role: Collaborator
Start: Jun 3, 2017
Completion: Feb 22, 2019
NCT03407651
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Phase: Phase 2
Start: Dec 18, 2017
Completion: Apr 13, 2019
NCT03995784
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
Start: Jun 18, 2019
Completion: Apr 30, 2020
NCT04072237
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Start: Sep 24, 2019
Completion: Jun 17, 2020
NCT04489537
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
Phase: Phase 3
Start: May 4, 2021
Completion: Dec 1, 2021
NCT04548791
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
Phase: Phase 1/2
Start: May 17, 2021
Completion: Dec 3, 2021
NCT05072912
Screening Study to Identify Patients With Complement Factor I Deficiencies
Phase: N/A
Start: Jul 21, 2021
Completion: Nov 23, 2021
NCT05095623
A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease
Start: Aug 31, 2021
Completion: Feb 10, 2022